JNJ - Johnson & Johnson
134.47 0.00 (0.00%)
Pre-Market: 8:00AM EDT
| Previous Close | 132.48 |
| Open | 132.45 |
| Bid | 134.59 x 900 |
| Ask | 134.87 x 1000 |
| Day's Range | 132.19 - 135.00 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 6,701,056 |
| Avg. Volume | 6,504,630 |
| Market Cap | 360.751B |
| Beta | 0.60 |
| PE Ratio (TTM) | 267.34 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.60 (2.68%) |
| Ex-Dividend Date | 2018-08-27 |
| 1y Target Est | N/A |
- PR Newswire•12 days ago
Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations
Mr. DelOrefice has been with Johnson & Johnson for 19 years and has most recently served as the CFO of the North America Hospital Medical Devices (MD) Business. Mr. DelOrefice holds a Bachelor of Science and MBA from Villanova University, and received his CPA certification from the Commonwealth of PA.
- PR Newswire•13 days ago
Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13 th Annual Healthcare Conference on Thursday, Sept. 6 th , at The Westin Boston ...
- PR Newswire•13 days ago
Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6 th , at the InterContinental, Boston ...
- ACCESSWIRE•last month
Free Research Report as Johnson & Johnson's Quarterly Earnings Advanced 14.75%
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.
- ACCESSWIRE•last month
Today's Research Reports on Stocks to Watch: Johnson & Johnson and Avid Bioservices
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.
- PR Newswire•last month
Johnson & Johnson Reports 2018 Second-Quarter Results:
2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017 2018 Second-Quarter EPS was $1.45 2018 Adjusted Second-Quarter EPS of $2.10 increased 14.8%* Accelerating Operational Sales Growth ...
- ACCESSWIRE•last month
Johnson & Johnson to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Johnson & Johnson (NYSE: JNJ ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 17, 2018 at 8:30 AM Eastern Time. To listen ...
- PR Newswire•last month
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018
NEW BRUNSWICK, N.J., July 16, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on September 11, 2018 to shareholders of record at the close of business on August 28, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
- ACCESSWIRE•last month
Today's Research Reports on Stocks to Watch: Biocept and Johnson and Johnson
NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Johnson & Johnson shares saw a drop on Friday as traders reacted to last week’s court decision that the company owes $4.69 billion to 22 women over its talc-based products allegedly causing them cancer. The company is vehement on appealing the court order. Biocept shares were skyrocketing on an announcement that it has entered into an agreement with Alliance Global FZ to market and distribute liquid biopsy testing in the Middle East, Southeast Asia, and the Africa region.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Johnson & Johnson and AstraZeneca
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...
- PR Newswire•last month
Johnson & Johnson's Official Statement in Response to Today's Verdict in St. Louis Trial
NEW BRUNSWICK, N.J., July 12, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) issued the following statement regarding today's verdict in the St. Louis court. "Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process that allowed plaintiffs to present a group of 22 women, most of whom had no connection to Missouri, in a single case all alleging that they developed ovarian cancer.
- PR Newswire•last month
St. Louis Jury Returns $4.69 Billion Verdict in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer
The six-man, six-woman jury in Judge Rex M. Burlison's 22nd Judicial Circuit Court in St. Louis heard six weeks of testimony and deliberated eight hours before returning the verdict. While there have been other trials in which juries have determined that talc products contained asbestos and caused mesothelioma cancer, this case marks the first talc/asbestos-induced ovarian cancer verdict in the United States.
- ACCESSWIRE•last month
Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks
On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).
- PR Newswire•2 months ago
Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
TITUSVILLE, N.J., June 26, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson and Johnson & Johnson Innovation LLC are joining with Mental Health America, OneMind, PeaceLove and other leading mental health and arts organizations to leverage the power of artistic creation to break down stigma about mental illnesses and build greater empathy and understanding. Champions of Science: The Art of Ending Stigma, a new global project, encourages all people to share artistic expressions about mental illnesses and the importance of overcoming stigma, while also educating about the biological basis of these diseases.
- PR Newswire•2 months ago
Johnson & Johnson Appoints Senior Leaders to Executive Committee
NEW BRUNSWICK, N.J. , June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the appointment of a number of senior leaders to the Company's Executive Committee. Specifically: Joaquin ...
- PR Newswire•2 months ago
Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson
NEW BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that Sandra (Sandi) E. Peterson, Group Worldwide Chairman for Johnson & Johnson, has announced her plans to retire from J&J effective October 1, 2018. During her career at Johnson & Johnson, Ms. Peterson exercised strong portfolio discipline in the businesses she has led, clarifying priority markets and segments, and shepherding numerous deals, acquisitions and divestitures. During her tenure, the Consumer business performance showed solid improvement, the U.S. OTC business was restored to growth, and the Vision Care business regained market leadership in contact lenses and has become a leader in eye health. In the past year, the Medical Device sector has made progress strengthening its foundation to improve performance and accelerate growth. Sandi has been instrumental in developing new partnerships in the areas of data science and technology for J&J.
- PR Newswire•2 months ago
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 19, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results. Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President, Chief Financial Officer will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
- PR Newswire•2 months ago
FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio
Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction Only available LASIK platform indicated for monovision LASIK in presbyopic myopic ...
- PR Newswire•2 months ago
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.
BOSTON , June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation ...
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Southwestern Energy, Johnson & Johnson, Sleep Number, QUALCOMM, Kirkland's, and Grupo Aval Acciones y Valores S.A — New Research Emphasizes Economic Growth
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southwestern ...
- PR Newswire•2 months ago
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J., June 12, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products. The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses.
- PR Newswire•2 months ago
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
NEW BRUNSWICK, New Jersey, June 13, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products. The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses.
- PR Newswire•2 months ago
Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)
NEW BRUNSWICK, N.J., June 6, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has received a binding offer from Fortive Corporation (FTV) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds from Fortive and $0.1 billion of retained net receivables. From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies (JNJ), has made significant contributions to surgery for more than 60 years.
- PR Newswire•2 months ago
Johnson & Johnson Announces Progress Toward Health for Humanity Goals
Annual Health for Humanity Report Discloses Progress on Global Commitments and Highlights Key Achievements Toward Eradicating and Preventing Disease, Reimagining Care Delivery and Promoting Lifelong Health ...
- PR Newswire•3 months ago
James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research
BOSTON, June 4, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today named James Allison, Ph.D., of University of Texas MD Anderson Cancer Center, winner of the 2018 Dr. Paul Janssen Award for Biomedical Research, and launched several new programs as part of our Champions of Science platform to fuel public engagement, support and trust in science. "Dr. Allison's innovative approach to treating cancer through harnessing the power of the immune system has led to breakthrough therapies that are providing hope for patients around the world," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson.